

We need your help to develop new therapies for Thyroid Eye Disease (TED)

What is the THRIVE clinical study?

THRIVE is a phase 3 clinical study exploring an investigational study drug called VRDN-001* as a potential new treatment for people living with TED. In THRIVE, researchers are looking to better understand the safety of the study drug and how it may benefit those diagnosed with moderate to severe active TED.

Who can participate in THRIVE?

18+

at least
18 years old



diagnosed with
active TED

≤15

symptoms started in
the last 15 months

This is not a complete list of the THRIVE eligibility requirements.
Please speak to a study doctor to review the full list inclusion and exclusion criteria.

What should I expect if I participate in THRIVE?



Attend study visits involving
medical tests and exams over
the course of about 52 weeks



During the first 15 weeks, 5
infusions of study drug or
placebo, once every 3 weeks**



Study drug or placebo given
by infusion through a vein in
the arm by a trained
professional



All study-related care, medical
tests and monitoring
conducted at no cost and
without co-pays



Some study visits can be done
at the home



Travel, hotel and other related
costs may be reimbursed

Participants who do not experience benefit after the first 15 weeks may be eligible to enter a separate open-label extension study to receive the study drug.

To learn more about the THRIVE clinical study, please visit [clinicaltrials.gov \(NCT05176639\)](https://clinicaltrials.gov/NCT05176639)

If you would like to learn more about Viridian, the study sponsor, please email patientadvocacy@viridiantherapeutics.com.

